Premedication to Reduce Amivantamab Associated Infusion Related Reactions (NCT05663866)
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
Who can join: Review the eligibility criteria below.
Location: Compassionate Cancer Care — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Compassionate Cancer Care — Fountain Valley, California
- Virginia Cancer Specialists — Fairfax, Virginia
- UW Medicine Valley Medical Center — Renton, Washington
- CHU de Brest - Hopital de la Cavale Blanche — Brest,
- Centre Leon Berard — Lyon,
- Hopital Cochin — Paris,
- Hopital Europeen Georges-Pompidou — Paris,
- CHU Rouen Hopital Charles Nicolle — Rouen,
- Nouvel Hopital Civil - CHU Strasbourg — Strasbourg,
- Chungbuk National University Hospital — Cheongju-si,
- National Cancer Center — Gyeonggi-do,
- Gachon University Gil Medical Center — Incheon,
- Chonnam National University Hwasun Hospital — Jeollanam-do,
- Seoul National University Bundang Hospital — Seongnam-si,
- Asan Medical Center — Seoul,
- Hosp. de La Santa Creu I Sant Pau — Barcelona,
- Hosp Univ Vall D Hebron — Barcelona,
- Hosp. Univ. Quiron Dexeus — Barcelona,
- Hosp. San Pedro de Alcantara — Cáceres,
- Hosp. de Jerez de La Frontera — Jerez de la Frontera,
- Inst. Cat. Doncologia-H Duran I Reynals — L'Hospitalet de Llobregat,
- Hosp. Gral. Univ. Gregorio Maranon — Madrid,
- Hosp. Univ. 12 de Octubre — Madrid,
- Hosp Virgen de La Victoria — Málaga,
- Hosp. Univ. Son Espases — Palma de Mallorca,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.